🔦 🔍💡 Chemsex: when pleasure, desire and consent are altered by substances, clinical guidelines must go beyond just infectious risks. This synthesis shows how to secure sessions while reconstructing a chosen sexuality. #Chemsex #SexualHealth #healthpractices (p. 1–7).
📌 This text is useful for doctors, sexologists, addiction specialists, psychologists, sexual health teams, CeGIDD, CSAPA and community associations, as it directly links chemsex, sexual disorders, consent and care organisation (p. 1–6).It allows for the identification of concrete severity signals, such as "100% substance-related sexuality", desire disorders, difficulties with erection or orgasm, and situations of chemical vulnerability (p. 1, 4–5).It primarily provides an operational framework to structure coordinated care between sexology, addiction, mental health and sexual health, without a judgemental stance (p. 5–7)
📜🔗 LINK to the source
1. Analytical summary
Context and issues
The article describes chemsex as a specific form of sexualised substance use, primarily among MSM, in often long, multi-partner sessions organised via apps, with products such as cathinones, methamphetamine, and GHB/GBL (p. 1–2).
The authors show that this practice cannot be understood solely by the products consumed: it is also embedded in social and community determinants, notably stigma, minority stress, sexual performance norms, and sometimes pre-existing vulnerabilities such as trauma or previous sexual difficulties (p. 3–4).
Operational contributions
The article provides precise clinical markers on the sexological effects of chemsex: short-circuiting of desire, prolonged excitatory plateau, erectile and ejaculatory disorders, decreased satisfaction, reduction of the erotic repertoire, and progressive dependence on a sexuality solely under substances (p. 1, 4–5).
It proposes an integrated care approach, based on two axes: securing sessions with substances and developing a non-consuming, diverse, realistic, and pleasure-oriented sexuality, in coordinated and non-judgmental pathways (p. 5–7).
2. Key points of the document
The "100% substance-based sexuality" is a major clinical warning signal : when a person can no longer envisage sexual intercourse without consumption, this should be considered a factor of severity and work should be done on reconstructing a sober or reduced-use sexuality (p. 1, 4–5).
Social determinants are central : chemsex is situated in a context of stigma, minority stress, masculinist norms, and a need for belonging, which influence entry into the practice and sometimes its severity (p. 3).
Sexual disorders are not secondary : the article details disorders of desire, erection, ejaculation, orgasm, and satisfaction, with sometimes a use of off-prescription iPDE5 in a logic of maintaining performance (p. 3–5).
Consent can be weakened by “chemical vulnerability” : the effects of substances, particularly GHB/GBL, can impair judgment, promote amnesia, loss of consciousness, and expose individuals to violence or non-consensual encounters (p. 4).
Care must be integrated and coordinated : the authors advocate for a connection between sexology, addiction, psychiatry, sexual health, prevention, and harm reduction, with strong links to the associative fabric and peer support (p. 5–7).
3. Action points for local actors
Systematically identify “100% under substances” sexuality in general medicine, sexual health, addiction, or mental health consultations, in order to early identify situations of functional dependency between sexuality and consumption (p. 1, 4–5).
Establish a cross-evaluation of sexology/addiction distinguishing what happens with and without substances: desire, arousal, orgasm, satisfaction, types of substances, contexts of use, harm, craving, non-consensual events, and trauma (p. 4–6)
Integrate consent into all chemsex interventions by working on the notion of chemical vulnerability, loss of consciousness, amnesia, power dynamics, and situations of sex for products, particularly in community settings and support groups (p. 4).
Develop targeted sexological support to restore desire, orgasm, the diversity of erotic scenarios, and a sexuality less exclusively focused on performance and endurance (p. 5–6).
Strengthen integrated pathways and combined prevention : repeated screenings for HIV/STI/HCV, PrEP/PEP, vaccinations, sterile equipment, education on GHB/GBL and slam, peer support, and community outreach (p. 5–6).
4. Additional references
🔍➕ For more information, see the articles referenced by "Health Practices" on the topic of sexual health ➡️🔗 https://pratiquesensante.odoo.com/blog/annonce-28/tag/sante-sexuelle-203To support chemsex users, resources are needed to innovate, cooperate, and act as closely as possible to individuals
Choi EPH et al. Web-Based Harm Reduction Intervention for Chemsex in Men Who Have Sex With Men: Randomized Controlled Trial (2023). This study usefully complements the article by demonstrating the value of a web-based harm reduction programme to improve refusal skills and reduce chemsex behaviours in the short term. https://pubmed.ncbi.nlm.nih.gov/36602853/
Coronado-Muñoz M et al. Sexualized drug use and chemsex among men who have sex with men in Europe: a systematic review and meta-analysis (2024). This review complements the European epidemiological framework on prevalence, substances used, and associated risks. https://www.mdpi.com/2077-0383/13/6/1812
5. Frequently Asked Questions (FAQ)
Does chemsex only concern drug use in a sexual context?
No. The article reminds us that chemsex is a particular form of sexualised substance use, mainly observed among MSM, with certain substances and planned sessions, distinct from other broader forms of sexualised drug use (p. 1–2).
What sexual disorders should make one think of the impact of chemsex?
The authors mainly cite desire short-circuiting, erectile dysfunction, delayed or impossible ejaculation, difficulty accessing orgasm, and decreased sexual satisfaction (p. 1, 4–5).
Why is the question of consent central?
Because certain substances significantly impair discernment, memory, and the ability to consent freely, particularly GHB/GBL, which exposes individuals to violence and abusive situations (p. 4).
How to distinguish compulsive sexual behaviour from the effects of substances?
The article recommends looking at whether the loss of control persists outside of intoxication and in other contexts; otherwise, the repetition may be more related to the substances and learned sexual scripts (p. 4).
Should one aim for sexual abstinence?
Not systematically. The authors explain that this question should be discussed on a case-by-case basis, from a clinical and ethical perspective, without imposing a single option on the patient (p. 6).
What should a prevention strategy adapted to chemsex contain?
A useful prevention strategy should articulate risk reduction related to substances, HIV/STI/HCV prevention, PrEP/PEP, access to sterile equipment, work on consent, and sexological dimensions related to desire and pleasure (p. 6).
Why work with associations and peers?
Because the article highlights that links with the associative fabric, peer support, and community outreach improve the acceptability of interventions and promote change (p. 6).
6. Rewriting in Easy Language
What does the document talk about?
Chemsex is taking substances to have sexual relations (p. 1).
This mainly concerns men who have sex with men (p. 1–2).
The most cited substances are cathinones, methamphetamine, and GHB/GBL (p. 1–2).
Chemsex can change desire, pleasure, and the way sexuality is experienced (p. 1, 4–5).
What problems have been identified?
Some people can no longer make love without substances (p. 1, 4–5).
Desire may disappear in favour of direct excitement (p. 4–5).
Erection, ejaculation, or orgasm can become difficult (p. 4–5).
Consent may be less clear due to substances (p. 4).
There may be violence or situations of coercion (p. 4).1
What support is offered?
Care must address both sexuality and substance use (p. 5–6).
Professionals must be non-judgmental (p. 6–7).
It is necessary to help the person regain a chosen and enjoyable sexuality (p. 5–7).
Prevention must also address pleasure, consent, and boundaries (p. 6).
7. Cross-sectional analysis — values of health practices
Literacy : the document remains expert, but it contains useful guidelines for adapting prevention and care messages to different levels of understanding, particularly regarding the risks associated with GHB/GBL and slam (p. 5–6)
Empowerment : the advocated approach seeks to help each person define their desires, limits, and care objectives, without imposing standardised abstinence (p. 5–7).
Participation : the role of the associative fabric, peer support, and community resources is clearly recognised in care pathways (p. 6).
Community health : the reading of chemsex is rooted in the social, cultural, and community realities of MSM, and not just in an individual risk approach (p. 3, 6–7).
Ethics : the text emphasises non-stigmatisation, consent, discussion around abstinence, and respect for each person's unique journey (p. 4, 6).
Human rights : the proposed approach explicitly aims for inclusion, combating stigmatisation, and better consideration of minority sexualities (p. 3, 6–7).
Intersectorality : the article recommends coordinated work between infectious diseases, sexology, addiction, psychiatry, prevention, and community actors (p. 5–7).1
Partnership : integrated, coordinated pathways with clear entry points are valued as an organisational model (p. 5–6).
Combating discrimination : the authors clearly link usage to minority stress, stigmatisation, and the violence experienced by MSM (p. 3–4)
8. Evaluation of the reliability of the resource
From a scientific perspective, this is a narrative review article published in an identified medical journal, with a provided and recent bibliography, mobilising international and French work, without claiming the completeness of a systematic review (p. 1–3, 7).
From an operational perspective, the resource is solid for field professionals, as it formulates concrete clinical benchmarks, warning signals, coordination principles, and prevention axes that can be directly mobilised in care and support pathways (p. 4–7).